THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

For biotechs, the IPO has lost its luster

By Jeffrey Krasner
Globe Staff / May 15, 2006

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size – +

For biotechnology companies, the initial public offering isn't what it once was. Venture capitalists and financiers say the so-called IPO window remains open. But only biotech companies with desirable, late-stage drug candidates and the right kind of deals with pharmaceutical companies will be able to sell shares to the public at high prices. (Full article: 782 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $4.95 1 article
  • $9.95 4 articles
  • $25.95 Monthly